Anticoagulation strategies for patients undergoing percutaneous coronary intervention: Unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors

Progress in Cardiovascular Diseases

Volumn 46, Issue 6, 2004, Pages 506-523

  Kokolis, Spyros ^a   Cavusoglu, Erdal ^a   Clark, Luther T ^a   Marmur, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ARGATROBAN; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; REVIPARIN; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HEMATEMESIS; HEMATURIA; HUMAN; ISCHEMIA; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

EID: 2942750024     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2004.02.002     Document Type: Article

References (93)

1. Hirsh J., Warkentin T.E., Raschke R., et al. Heparin and low molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest. 114:(5 Suppl):1998;489S-510S
2. Warkentin T.E., Crowther M.A. Reversing anticoagulants both old and new. Can J Anaesth. 49:2002;S11-S25
3. Linhardt R.J., Gunay N.S. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 25:(Suppl 3):1999;5-16
4. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost. 22:1996;117-124
5. Rosenberg R.D., Oosta G.M., Jordan R.E., et al. The interaction of heparin with thrombin and antithrombin. Biochem Biophys Res Commun. 96:1980;1200-1208
6. Ofosu F.A., Barrowcliffe T.W. Mechanisms of action of low molecular weight heparins and heparinoids. Hirsh J. Antithrombotic Therapy, Baillieres Clinical Haematology. vol 3:1990;505-529 Bailliere Tindall, London
7. Rosenberg R.D., Bauer K.A. The heparin-Antithrombin system A natural anticoagulant mechanism. Colman R.W., Hirsch J., Marder V.J.,, et al. Hemostasis and Thrombosis Basic Principles and Clinical Practice. 3rd ed. 1994;837-860 Lippincott, Philadelphia, PA
8. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 337:1997;688-698
9. Anderson W., Harthill J.E. Molecular weight dependence of heparin anti-factor Xa activity Influence of method. Thromb Res. 21:1981;557-564
10. Danielsson A., Raub E., Lindahl U., et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 261:1986;15467-15473
11. Rosenberg R.D., Jordan R.E., Favreau L.V., et al. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun. 86:1979;1319-1324
12. Jordan R.E., Favreau L.V., Braswell E.H., et al. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem. 257:1982;400-406
13. Weitz J.I., Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 97:1998;544-552
14. Duplaga B.A., Rivers C.W., Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 21:2001;218-234
15. Marmur J.D., Anand S.X., Bagga R.S., et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol. 41:2003;394-402
16. Leizorovicz A., Bara L., Samama M.M., et al. Factor Xa inhibition Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 23:(Suppl 1):1993;89-98
17. Bara L., Planes A., Samama M.M. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 104:1999;230-240
18. ENOX Test Card. 2002;Pharmanetics, Inc, Morrisville, NC. [package insert]
19. Caranobe C., Barret A., Gabaig A.M., et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res. 40:1985;129-133
20. Palm M., Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 58:1987;932-935
21. Collet J.P., Montalescot G., Choussat R., et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 80:2001;81-82
22. Lovenox. 2003;Aventis Pharmaceuticals, Inc, Bridgewater, NJ. (enoxaparin sodium injection) [package insert]
23. Crowther M.A., Berry L.R., Monagle P.T., et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 116:2002;178-186
24. Bates S.M., Weitz J.I. Direct thrombin inhibitors for treatment of arterial thrombosis Potential differences between bivalirudin and hirudin. Am J Cardiol. 82:1998;12P-18P
25. Fenton J.W., Villanueva G.B., Ofosu F.A., et al. Thrombin inhibition by hirudin How hirudin inhibits thrombin. Haemostasis. 21:(Suppl 1):1991;27-31
26. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 25:1986;4622-4628
27. Maraganore J.M., Bourdon P., Jablonski J., et al. Design and characterization of hirulogs A novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 29:1990;7095-7101
28. Hursting M.J., Alford K.L., Becker J.C., et al. Novastan (brand of argatroban) A small-molecule direct thrombin inhibitor. Semin Thromb Hemost. 23:1997;503-516
29. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes Principal results of a meta-analysis based on individual patient's data. Lancet. 359:2002;294-302
30. Robson R., White H., Aylward P., et al. Bivalirudin pharmacokinetics and pharmacodynamics Effect of renal function, dose, and gender. Clin Pharmacol Ther. 71:2002;433-439
31. Maraganore J.M., Adelman B.A., Hirulog. A direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis. 7:1996;438-448
32. Maraganore J.M. Hirudin and Hirulog Advances in antithrombotic therapy. Perspectives in Drug Discovery and Design. 1:1993;461-478
33. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 25:1986;4622-4628
34. Greinacher A., Lubenow N. Recombinant hirudin in clinical practice Focus on lepirudin. Circulation. 103:2001;1479-1484
35. Eikelboom J.W., Anand S.S., Mehta S.R., et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation. 103:2001;643-650
36. Greinacher A. Recombinant hirudin for treatment of heparin-induced thrombocytopenia. Warkentin T.E., Greinacher A. Heparin-Induced Thrombocytopenia. 2000;313-338 Marcel Dekker, New York
37. Stringer K., Lindenfield J. Hirudins Antithrombin anticoagulants. Ann Pharmacother. 26:1992;1535-1540
38. Potzsch B., Hund S., Madlener K., et al. Monitoring of recombinant hirudin Assessment of a plasma-based ecarin clotting time assay. Thromb Res. 86:1997;373-383
39. Schiele F., Vuillemenot A., Kramarz P., et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol. 50:1995;20-25
40. Song X., Huhle G., Wang L., et al. Generation of Anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 100:1999;1528-1532
41. Agatroban injection. 2003;GlaxoSmithKline, Research Triangle Park, NC. [package insert]
42. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes Principal results of a meta-analysis based on individual patients' data. Lancet. 359:2002;294-302
43. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 100:1999;1593-1601
44. Cohen M., Demers C., Gurfinkel E.P., et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events. Am J Cardiol. 82:1998;9L-24L
45. Wallentin L., Bergstrand L., Dellborg M., et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction - The ASSENT Plus study. Eur Heart J. 24:2003;897-908
46. Wallentin L., Husted S., Kontny F., et al. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol. 80:1997;61E-63E
47. James S., Armstrong P., Califf R., et al. Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J. 23:2002;1538-1545
48. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med. 337:1997;447-452
49. Collet J.P., Montalescot G., Lison L., et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 103:2001;658-663
50. Ferguson J.J., Antman E.M., Bates E.R., et al. The use of enoxaparin and GPIIb/IIIa antagonists in acute coronary syndromes. Final results of the NICE 3 study. J Am Coll Cardiol. 37:(2 Suppl A):2001;1253-1297. [abstract]
51. Kereiakes D.J., Grines C., Fry E., et al. The NICE 1 and NICE 4 Investigators, National Investigators Collaborating on Enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol. 13:2001;272-278
52. Bhatt D.L., Lee B.I., Casterella P.J., et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention Results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J Am Coll Cardiol. 41:2003;20-25
53. Arjomand H., Surabhi S.K., Cohen M. Unfractionated versus fractionated heparin for percutaneous coronary intervention. Curr Cardiol Rep. 4:2002;327-333
54. Karsch K.R., Preisack M.B., Baildon R., et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol. 28:1996;1437-1443
55. Cavasoglu E., ElRouby S., Kunamneni P.B., et al. Monitoring low molecular weight heparin during interventional coronary procedures using sensitive point of care assay. Blood. 102:2003;1171
56. Kereiakes D.J., Kleiman N.S., Fry E., et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J. 141:2001;348-352
57. Legalery P., Seronde M.F., Schiele F., et al. Enoxaparin as antithrombotic treatment in patients subject to percutaneous coronary interventions Comparison with unfractionated heparin. Am J Cardiol. 90:(Suppl 6A):2002;163H. [abstract]
58. Young J.J., Kereiakes D.J., Grines C.L. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol. 12:(Suppl E):2000;E14-E18
59. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet. 352:1998;87-92
60. Esprit Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) A randomised, placebo-controlled trial. Lancet. 356:2000;2037-2044
61. Choussat R., Montalescot G., Collet J.P., et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol. 40:2002;1943-1950
62. Gerlach A.T., Pickworth K.K., Seth S.K., et al. Enoxaparin and bleeding complications A review in patients with and without renal insufficiency. Pharmacotherapy. 20:2000;771-775
63. Collet J.P., Montalescot G., Choussat R., et al. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 80:2001;81-82
64. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 142:2001;952-959
65. Reed M.D., Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 22:2002;105S-111S
66. Kleiman N.S., Klem J., Fernandes L.S., et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 143:2002;585-593
67. Kleiman N.S., Lincoff A.M., Sapp S.K., Maresh K.J., Topol E.J. Pharmacodynamics of a direct thrombin inhibitor combined with a GP IIb-IIIa antagonist First experience in humans. Circulation. 100:(Suppl 18):1999;I328. [abstract]
68. Kleiman N.S., Lincoff A.M., Harrington R.A., et al. Antithrombin, antiplatelet therapy or both during PCI A preliminary randomized trial. J Am Coll Cardiol. 37:(2 Suppl A):2001;. [abstract], 1293-1242
69. Lincoff A.M., Bittl J.A., Kleiman N.S., et al. REPLACE Investigators. The REPLACE 1 Trial A Pilot Study of Bivalirudin Versus Heparin During Percutaneous Coronary Intervention With Stenting and GP IIb/IIIa Blockade. J Am Coll Cardiol. 39:(5 Suppl A):2002;16A. [abstract]
70. Lincoff A.M., Kleiman N.S., Kottke-Marchant K., et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 143:2002;847-853
71. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention REPLACE-2 randomized trial. JAMA. 289:2003;853-863
72. Campbell K.R., Mahaffey K.W., Lewis B.E., et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol. 12:(Suppl F):2000;14F-19F
73. Campbell K.R., Wildermann N., Janning C., et al. ATBAT Investigators. Bivalirudin during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia Interim results of the ATBAT Trial. Am J Cardiol. 86:(Suppl 8A):2000;73i-74i. [abstract]
74. Bhatt D.L., Cho L., Lincoff A.M., et al. Reduction in percutaneous coronary intervention-related bleeding with bivalirudin is particularly striking in women. J Am Coll Cardiol. 39:(5 Suppl A):2002;1053-1054. [abstract]
75. Aguirre F.V., Gill J.B. Increasing benefit, reducing risk Focusing on hemorrhagic complications in percutaneous coronary intervention. J Invasive Cardiol. 14:(Suppl B):2002;48B-54B
76. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation A randomised trial. Lancet. 353:1999;429-438
77. Eikelboom J., Anand S.S., Mehta S.R., et al. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation Organization to assess strategies for ischemic syndromes (OASIS-2) study. Circulation. 103:2001;643-650
78. Serruys P.W., Herrman J.P., Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med. 333:1995;757-763
79. Matthai W.H. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost. 25:(Suppl 1):1999;57-60
80. Lewis B.E., Matthai W.H., Cohen M., et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheterization Cardiovasc Interv. 57:2002;177-184
81. Lewis B.E., Mathai W., Grassman E.D. Results of a phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia. Circulation. 96:(Suppl):1997;I-217. [abstract]
82. Moledina M., Chakir M., Gandhi P.J. A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis. 12:2001;141-149
83. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682
84. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11
85. Moscucci M., Share D., Kline-Rogers E., et al. The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) collaborative quality improvement initiative in percutaneous coronary interventions. J Interv Cardiol. 15:2002;381-386
86. Ahmed W.H., Piana R.N., Bittl J.A. Does bleeding cause ischemic events after coronary angioplasty? Circulation. 94:(8 Suppl I):1996;I-376. [abstract]
87. Bittl J. Switching from heparin to a thrombin-specific anticoagulant (bivalirudin) for PTCA in unstable angina patients reduces major clinical events. Circulation. 102:(18 Suppl):2000;813. [abstract]
88. Weitz J.I., Hudoba M., Massel D., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors. J Clin Invest. 86:1990;385-391
89. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696
90. Kereiakes D.J., Fry E., Matthai W., et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention "NICE guys finish first" J Invasive Cardiol. 12:(Suppl A):2000;1A-5A
91. Adamian M., Mehran R., Mintz G.S., et al. Safety and feasibility of direct thrombin inhibitor bivalirudin during percutaneous coronary interventions in patients with chronic renal failure. Results of the pilot study. Am J Cardiol. 90:(Suppl 6A):2002;162H. [abstract]
92. Adamian M., Farkouh M., Mehran R., et al. A matched comparison of safety and feasibility of bivalirudin in patients with diabetes mellitus during percutaneous coronary interventions. Am J Cardiol. 90:(Suppl 6A):2002;161H. [abstract]
93. Cho L., Chew D.P., Moliterno D.J., et al. Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. Am J Cardiol. 91:2003;742-743